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for the pound?” At least, that is what they should ask if
they desire an NHS that can keep them healthy and
safe at an affordable price for as long as is feasible.
Donald M Berwick president
Institute for Healthcare Improvement, 20 University Road, Cambridge
MA 02138, USA
(dberwick@ihi.org)
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Treatment of staphylococcal infection
Prescriptions must be part of a package that includes infection control
We have seen a spectacular rise in multiresist-ant Staphylococcus aureus (usually termedmethicillin resistant Staphylococcus aureus—
MRSA) in hospitals and care homes in the United
Kingdom in the past five years.1 The emergence and
spread of modern resistant bacteria are not simply the
result of mutations or gene transfer in the diverse spe-
cies we call S aureus,2 as occurred when resistance first
developed.3 Instead the resistance is now spread by the
dissemination of a tiny number of clones, which have a
predisposition towards resistance and have been
selected by current treatment. So how does one treat
staphylococcal infection?
In particular, two clones, epidemic MRSA
(EMRSA)-15 and EMRSA-16, account for more than
95% of MRSA strains isolated in the United Kingdom.4
The carriage of resistance in these bacteria seems to be
associated with no fitness cost—the acquisition of
resistance does not slow the growth of the bacteria and
thus put them at a selective disadvantage once the anti-
biotic is removed.5 So now the prescriber is faced with
a different problem, the widespread dissemination of a
limited number of virulent MRSA types. These can
persist for long periods and have a predisposition
to acquire further resistance genes readily, which
could mean that these resistant clonal strains will
become pan-resistant and completely untreatable with
antibiotics.
When considering treatment options, prescribers
have two responsibilities. The first and most immediate
is to the patient. For the patient, the most effective
treatment is the best choice. However, this considera-
tion alone has not stemmed the rise in resistance. So
prescribers also have to consider the impact of the
antibiotic on the levels of resistant bacteria. Develop-
ment of resistance is a two stage process. The first stage
is the initial emergence of resistant strains, and the next
is their dissemination. The first stage could occur in a
non-clinical situation, such as during animal hus-
bandry.6 This is possible but unlikely. Once resistance
has become established, even low drug usage can
maintain it or even increase its spread in the
population. Most antibiotic prescribing facilitates the
dissemination of clonal resistant bacteria, and this is
where precautions need to be planned carefully.
If we consider MRSA in the United Kingdom, we
find strains that are highly resistant to all but a few anti-
biotics, which generally include the glycopeptides. So the
glycopeptides vancomycin and teicoplanin may still be
used cautiously. This means prescribers should be aware
that intermediate resistance to vancomycin has been
reported,7 they should find out if resistance has been
reported in their immediate area, and also keep in mind
that these resistant bacteria would be encouraged and
their numbers increased by individual prescription of
these drugs. Clinical resistance to high concentrations of
glycopeptides has emerged by transfer of the vanA
operon from vancomycin resistant enterococci into
MRSA in the United States.8 Therefore, vancomycin
resistant MRSA now only has to disseminate, and every
prescription for glycopeptides will support this. So the
choice to prescribe a glycopeptide must be based on
the local risk of favouring the spread of glycopeptide
resistant clones.
What are the alternatives? These are not found in
our usual armamentarium but with the oxolinidones,
daptomycin, and streptogrammins. These drugs can be
effective in certain situations but are unlikely to
become the universal panacea for the treatment of sta-
phylococcal infections. The US Veterans Health
Administration recommends that these drugs should
generally be reserved for serious infections for which
no alternative antimicrobial treatment exists.9 It says
that any of these drugs could be used for complicated
infections of the skin or skin structure and one or more
of the following—proved resistance to vancomycin;
infection in patients who do not tolerate vancomycin
because of allergy or serious adverse drug reaction;
and failed treatment with vancomycin. It also says that
oral linezolid can be used only in patients suitable for
oral treatment for whom treatment with oral
trimethoprim-sulfamethoxazole, tetracyclines, fluoro-
quinolones, and clindamycin is inappropriate because
of microbial resistance or intolerance of these medica-
tions. It further recommends only linezolid for the
treatment of staphylococcal pneumonia but warns of
the risk of linezolid resistance and highlights the fact
that the US Food and Drug Administration does not
recommend the use of any of these drugs for the treat-
ment of endocarditis or bone and joint infections.
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Resistance to multiple antibiotics in S aureus is a
problem that all prescribers should consider if we are
to preserve our capability to treat infections. However,
we need to understand that what we are trying to con-
trol is the spread of the bacteria, which are already
resistant to most antibiotics, rather than the initial
emergence of resistance. With that in mind, prescrip-
tion must be part of a package that includes infection
control and the implementation of hygiene barriers
that prevent the cross infection of patients. Only then
would we have any prospect to reduce resistance suffi-
ciently to allow us to reintroduce the antibiotics we
used earlier.10 We also need to remember that antibiotic
treatment for Gram positive bacteria is often less effec-
tive at controlling Gram negative bacteria. Some
strains are pan-resistant and are now at least as difficult
to control as MRSA, and it would be ironical if we defer
one problem only to have to confront a worse one.
Sebastian G B Amyes professor of microbial chemotherapy
Medical Microbiology, Centre for Infectious Diseases, Medical School,
University of Edinburgh, Edinburgh EH8 9AG
(s.g.b.amyes@ed.ac.uk)
Competing interests: None declared.
1 Tiemersma EW, Bronzwaer SLAM, Lyytikäinen O, Degener JE, Schrijne-
makers P, Bruinsma N, et al. Methicillin-resistant Staphylococcus aureus
in Europe, 1999-2002. Emerg Infect Dis 2004;10:1627-34.
2 Fitzgerald JR, Musser JM. Evolutionary genomics of pathogenic bacteria.
Trends Microbiol 2001;9:547-53.
3 Courvalin P. The Garrod lecture. Evasion of antibiotic action by bacteria.
J Antimicrob Chemother 1996;37:855-69.
4 Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination
and fitness. Curr Opin Microbiol 1998;1:524-9.
5 Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones R, et al. Does the
use of antibiotics in food animals pose a risk to human health? A critical
review of published data. J Antimicrob Chemother 2004;53:28-52.
6 Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin sus-
ceptibility within methicillin-resistant Staphylococcus aureus lineages.
Emerg Infect Dis 2004;10:855-7.
7 Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin sus-
ceptibility within methicillin-resistant Staphylococcus aureus lineages.
Emerg Infect Dis 2004;10:855-7.
8 Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE,
et al. Genetic analysis of a high-level vancomycin-resistant isolate of
Staphylococcus aureus. Science 2003;302:1569-71.
9 Veterans Health Administration Pharmacy Benefits Management Strate-
gic Healthcare Group and the Medical Advisory Panel. Criteria for use of
linezolid (Zyvox™), quinupristin-dalfopristin (Synercid®), and daptomy-
cin (Cubicin™). www.vapbm.org/criteria/linezolidcriteria1.pdf (accessed
14 Feb 2005).
10 Vandenbroucke-Grauls CMJ. Methicillin-resistant Staphylococcus aureus
control in hospitals: the Dutch experience. Infect Control Hosp Epidemiol
1996;17:512-3.
Surveying the literature from animal experiments
Critical reviews may be helpful—not systematic ones
The value of animal research for finding newtreatments for human diseases is a continuingdebate. The starting point of the debate must
be the recognition of the past contributions of animal
experiments to our understanding of disease and
existing treatments. We can cite the major impact of
research based on animals in diseases such as polio,
kidney transplantation, and Parkinson’s disease.
Almost every form of conventional medical treatment
(including most drugs, surgical treatments, and
vaccines) was developed with the help of animal
research.1–3 Most of what we know about the basic
workings of the body—in humans and animals—has
come to us through two centuries of animal
experiments. Each decade of animal research has
brought newer and deeper understanding.4 What we
lack, however, are better methods of surveying the
literature on animal experiments.
Curiosity about fundamental biological mecha-
nisms has yielded a rich harvest of useful knowledge.
Although around 30% of current animal research is
categorised as “fundamental” by the Home Office,3
much of this targets specific diseases. How do we
know when the information gained from animal
experiments is strictly relevant for the planning of
clinical trials of new drugs?
It might seem straightforward to ensure that,
before a clinical trial of a new treatment commences,
all relevant results from animal studies are systemati-
cally reviewed for evidence of safety and efficacy. Per-
haps the best known case is that of the calcium
channel blocker nimodipine as a potential neuropro-
tective agent after stroke. Some authors have claimed
that animal experiments failed to prevent the
problems that occurred in the clinical trials.5 6 But ani-
mal experiments did reveal the deleterious effects of
this drug, and these results were published. The clini-
cal trials, however, went ahead despite evidence from
animal experiments that suggested caution. Why?
What are the pressures (scientific, commercial, and
others) that allow trials to progress even when the evi-
dence is not compelling or even ambiguous? And
what are the requirements to weigh all available
evidence in balance rather than select the data that
support the personal or economic imperative?
Although the example of nimodipine is well known,
other powerful recent examples of animal research
informing medical advance also exist—for example, the
recent development of a vaccine for the severe acute res-
piratory syndrome.7
We need better methods of surveying the literature
on animal experiments. The huge year on year
increase in the numbers of studies reported makes it
ever more likely that vital pieces of evidence go unde-
tected. However, the proposal that systematic reviews
of animal based research might solve this problem has
two fundamental problems. Firstly, no mechanism
exists for so called negative results to be published.
Thus the absence of evidence for a particular drug
action must often be inferred. This is not just an issue
of publication bias; it is intrinsic to the experimental
process. Scientific experiments are designed to test for
evidence in favour of a particular experimental
hypothesis and to abandon it if insufficient evidence is
acquired.
Secondly, the style of clinical trials and of animal
research have important generic differences. Clinical
trials of putative treatments entail testing the treatment
on a cohort of sick humans. The design can vary, but
the subjects can be quite similar from one trial to
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